Skip to main content
All lobbying filings

LEAVITT PARTNERS, LLC

LEAVITT PARTNERS, LLC filed a Q1 report for SAVE RARE TREATMENTS TASK FORCE on April 22, 2025, reporting $40,000 in lobbying income.

Lobbying for SAVE RARE TREATMENTS TASK FORCE · Dedicated to restoring the spirit of R&D incentives in the Orphan Drug Act.

All filings by LEAVITT PARTNERS, LLC · Everything SAVE RARE TREATMENTS TASK FORCE has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 22, 2025
Income
$40,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 2
  • ROBERT CLAYTON ALSPACH
    Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C
  • JOSH TRENT
    Previously held: Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

 Affiliated organizations 2

Section 6 of the LD-2: organizations that contribute to this lobbying or take an active part in directing it. On a trade association's filing, this is where its backers appear.

  • AGIOS PHARMACEUTICALS
    Cambridge, Massachusetts
  • ALKERMES, INC.
    Waltham, Massachusetts

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem